Browse the evidence

Incretin receptor activators (GLP-1RA and GIP/GLP-1 dual agonists) cause a reduction in skeletal muscle mass (SMM) that is proportional to fat loss, with approximately 5% of lean body mass lost for every 10% reduction in total body weight, potentially leading to sarcopenia in a subset of treated patients.

If you are taking GLP-1RA or similar weight-loss medications, be aware that you will lose some muscle along with fat. To minimize this, engage in structured exercise programs and discuss monitoring your muscle mass with your doctor, especially if you are older or have existing frailty.

The ratio of serum creatinine to cystatin C (Sarcopenia Index, SI) is a valid, non-invasive biomarker for estimating skeletal muscle mass and predicting mortality in sarcopenic populations, including those treated with GLP-1RA.

Ask your doctor about using a Sarcopenia Index (SI), calculated from your routine creatinine and cystatin C blood tests, to monitor your muscle health while on weight-loss medications. This simple calculation can help detect muscle loss early.

Orforglipron significantly improves lipid profiles, including reductions in total cholesterol, LDL cholesterol, and triglycerides, along with increases in HDL cholesterol, independent of weight loss magnitude.

Orforglipron not only helps with weight loss but also significantly improves heart health markers. It lowers bad cholesterol (LDL) and triglycerides while raising good cholesterol (HDL). These improvements occur alongside weight loss and contribute to a lower risk of cardiovascular disease, making it a comprehensive treatment for obesity-related metabolic risks.

Delaying the onset of type 2 diabetes by two years in individuals with obesity is associated with a 3.7-year increase in median life expectancy and reduced long-term mortality, primarily driven by lower cardiovascular mortality.

For individuals with obesity, preventing or delaying the onset of type 2 diabetes is a critical lever for extending life expectancy. This study suggests that even a modest two-year delay in developing diabetes can add nearly four years to your life, largely by protecting your heart. Focus on metabolic health markers (like blood sugar and insulin sensitivity) as aggressively as you focus on weight, as the timing of diabetes onset directly impacts how long you live.

Treatment with extended-release naltrexone/bupropion (NB) produces weight loss that is disproportionately derived from fat mass rather than lean mass compared to placebo, resulting in a favorable shift in the lean-to-fat mass ratio.

If you are using naltrexone/bupropion for weight loss, the medication helps you lose more fat and preserve more muscle than dieting alone. This is beneficial for long-term metabolic health. Ensure you are following a caloric deficit and staying active as instructed.

Consuming 50g of isomaltulose (ISO) as a preload before a mixed meal significantly enhances the secretion of gut hormones GLP-1, GIP, and PYY compared to sucrose (SAC), with a particularly pronounced effect on PYY levels in both healthy individuals and those with Type 2 Diabetes.

If you want to boost your gut hormones (GLP-1, PYY) which help regulate appetite and insulin, try eating 50g of isomaltulose (often found in products like Palatinose) about one hour before your main meal. This specific timing and dose triggers a much stronger hormonal response than regular table sugar (sucrose), especially regarding PYY, which is linked to satiety. Note that this did not significantly lower blood glucose in the subsequent meal in this study, so it is a tool for hormonal modulation, not necessarily glycemic control.

Dual and tri-agonists targeting GLP-1, GIP, and Glucagon receptors provide superior metabolic homeostasis and cardiovascular benefits compared to mono-agonists by leveraging cooperative hormonal signaling.

Current GLP-1 treatments are effective, but newer dual and triple hormone therapies (targeting GLP-1, GIP, and Glucagon receptors) offer broader metabolic and cardiovascular benefits. These are available as weekly or daily injections, and in some cases, oral formulations, addressing the burden of daily dosing.

A decrease in total energy intake is independently associated with a loss of muscle mass in patients with Type 2 Diabetes, even when adjusting for physical activity and hypoglycemic agents.

When reducing calories for Type 2 Diabetes, be aware that muscle mass may also decrease. To counteract this, ensure your diet includes adequate protein and incorporate resistance training. Monitoring body composition is important to ensure you are losing fat, not muscle.

Monogenic obesity caused by leptin deficiency can be effectively treated with recombinant leptin therapy, restoring normal appetite regulation.

This intervention is not for the general population. It applies only to a tiny fraction of individuals with confirmed monogenic leptin deficiency. Standard weight loss strategies remain the primary approach for >99% of cases.

Higher relative carbohydrate intake (42-51% of energy) causally reduces hypertension risk by 71% compared to lower intake, independent of protein and fat intake.

If you have hypertension, increasing your carbohydrate intake to represent 42-51% of your total daily energy may help lower your blood pressure risk, provided you adjust other macronutrients accordingly. This finding is based on genetic evidence from large European cohorts, suggesting a causal protective effect of relative carbohydrate intake over protein and fat.

The protective effect of higher carbohydrate intake on hypertension is mediated by improved psychological well-being and reduced adiposity.

Eating a diet with 42-51% of calories from carbohydrates may help lower blood pressure not just by weight management, but also by improving mental health and reducing stress-related factors like depression and anxiety.

Three-dimensional optical (3DO) imaging using the Fit3D ProScanner is a sensitive and accurate tool for monitoring longitudinal changes in body composition (total fat mass, fat-free mass, and appendicular lean mass) compared to dual-energy X-ray absorptiometry (DXA).

Use 3DO imaging (like Fit3D) to track your body composition changes over time rather than relying solely on scale weight. The technology is validated to detect small changes in fat and lean mass comparable to clinical DXA scans. For best results, take multiple scans and average them to minimize error, and focus on trends over weeks rather than day-to-day fluctuations.

High consumption of sugar-sweetened beverages (≥2 servings/day) increases cardiovascular disease risk by 15% even in individuals who meet physical activity guidelines.

If you drink two or more sugary beverages a day, your cardiovascular risk remains elevated even if you exercise regularly. While exercise is crucial for health, it does not completely cancel out the negative effects of high sugar intake. To minimize heart disease risk, limit sugary drinks regardless of your activity level.

Not meeting physical activity guidelines combined with high consumption of sugar-sweetened beverages (≥2 servings/week) is associated with a 47% higher risk of cardiovascular disease.

If you are not physically active, drinking sugary beverages frequently (≥2 servings/week) significantly increases your risk of heart disease. To lower your risk, you should aim to increase physical activity and reduce sugary drink intake.

Effective obesity medications (e.g., GLP-1/GIP agonists) work by lowering the adipose mass set point through counteracting adaptive hormonal responses, allowing homeostasis at a lower weight, but require lifelong use to maintain this new set point.

Obesity medications are not a temporary fix but a long-term management tool for a chronic disease. They work by resetting your body's biological 'thermostat' to a lower weight. If you stop taking them, your biology will fight to regain the weight. Therefore, these medications should be viewed as lifelong treatments, similar to blood pressure medication, to maintain your health.

Metabolic adaptation during weight loss involves a 15-20% reduction in daily energy expenditure beyond what is expected from mass loss, which persists until the previous weight is regained.

When you lose weight through dieting, your body burns 15-20% fewer calories than expected for your new size. This 'metabolic adaptation' does not go away over time; it stays until you regain the weight. This is why maintaining weight loss through diet alone is so difficult—you must eat significantly less than a healthy person of your new weight would.

GLP-1 receptor agonists (GLP-1RAs) reduce binge eating frequency and severity in patients with Binge Eating Disorder (BED) and Bulimia Nervosa (BN), likely by modulating central reward circuits and increasing satiety.

If you have BED or BN, GLP-1RAs like semaglutide or liraglutide can significantly reduce binge eating episodes by changing how your brain responds to food rewards and increasing fullness. This is supported by systematic reviews, though it is not a standalone cure and should be monitored by a clinician, especially given potential gastrointestinal side effects.

GLP-1 receptor agonists (semaglutide, tirzepatide) are highly effective pharmacologic interventions for obesity, producing significant weight loss and metabolic improvements, but their rapid expansion raises safety concerns regarding gastrointestinal side effects, rare serious adverse events, and long-term outcomes not captured in clinical trials.

GLP-1 medications like semaglutide and tirzepatide are currently the most effective non-surgical treatments for obesity, offering weight loss comparable to surgery for many. However, they are not without risks, including common gastrointestinal issues and rare serious side effects. It is crucial to use these medications under strict medical supervision, especially if you have other health conditions, to manage side effects and monitor for long-term safety.

Standard body composition metrics (DXA) overestimate muscle loss in obesity because they misclassify visceral and subcutaneous fat as 'lean body mass'; MRI-based 'adipose tissue-free muscle volume' provides a more accurate assessment of true muscle mass.

If you are using DXA scans to track muscle loss on GLP-1s, be aware that these machines often mistake visceral fat for muscle. This can make it look like you are losing more muscle than you actually are. Focus on functional strength (grip, lifting) rather than just the DXA number.

Fixed-ratio combinations (FRCs) of basal insulin and GLP-1 receptor agonists (GLP-1RA) provide superior glycemic control and weight loss compared to either component alone, but are limited by a low GLP-1RA dose relative to the insulin dose, making separate dosing preferable for obese patients requiring higher GLP-1RA doses.

Fixed-ratio combinations (like IDegLira, iGlarLixi, or IcoSema) are effective for lowering blood sugar and weight compared to using just insulin or just a GLP-1 drug. However, because the ratio of insulin to GLP-1 drug is fixed, these combinations often deliver too little GLP-1 drug for obese patients who need higher doses for maximum weight loss and glucose control. If you are obese or need high doses of GLP-1RA, separate injections of basal insulin and GLP-1RA allow you to titrate each drug independently to your optimal dose.

Roux-en-Y gastric bypass (RYGB) and Health Behavior Intervention (HBI) are cost-effective strategies for managing class III obesity, whereas current-price pharmacotherapies (semaglutide and tirzepatide) are not cost-effective compared to no treatment or HBI.

For individuals with class III obesity, Roux-en-Y gastric bypass offers the best long-term health outcomes and cost-effectiveness. Health Behavior Intervention (13 counseling sessions) is also cost-effective. Current GLP-1/GIP medications are not cost-effective at current prices, though lower prices could change this.

Antiobesity medications (AOMs) improve cardiovascular outcomes, hypertension, and metabolic liver disease in older adults, but their use requires caution due to an increased risk of sarcopenia.

For older adults, AOMs are a powerful tool to treat obesity-related health issues like heart disease and diabetes. However, because losing weight can also lead to muscle loss (sarcopenia), these medications should be used cautiously and monitored closely by a doctor, often alongside lifestyle changes.

Shifting nutrient absorption to the distal small intestine (ileum) significantly increases post-prandial GLP-1 and PYY secretion, improving glucose control and contributing to weight loss, as seen in bariatric surgery and with certain enzyme inhibitors.

Bariatric surgery works partly by forcing food to be digested further down the intestine, which triggers a strong hormone release (GLP-1/PYY) that helps control blood sugar and appetite. Some diabetes medications (like acarbose) mimic this by slowing digestion. This suggests that how and where food is absorbed matters as much as what is eaten.

GLP-1 receptor agonists (GLP-1RA) significantly reduce body weight and visceral fat, leading to improved cardiovascular and renal outcomes in T2DM patients.

For T2DM patients with heart or kidney risks, GLP-1 receptor agonists are a top choice. They help lower blood sugar, promote significant weight loss by reducing visceral fat, and protect the heart and kidneys. Discuss options like weekly injections or oral formulations with your doctor.